Since the approval of the first recombinant biotherapeutic, insulin, in 1982, the pharmaceutical industry has experienced an explosion in the development and commercialisation of protein therapeutics. The development and improvement of industrial manufacturing platforms has been a key enabler for
this. Dr. Jesús Zurdo, Andrea Gough and Dr Delphine Cougot at Horizon Discovery provide an overview on how monoclonal antibodies and architectures derived from them constitute more than half of the protein therapeutics on the market and are, by far, the largest group of biopharmaceuticals currently in clinical development.